Serum Vitamin D Levels in Chronic Hepatitis B Patients Before and During Treatment.
Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy. It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real time PCR; once before initiation of antiviral treatment and again at least 6 months later, serum vitamin D level [25(OH)D3; assessed twice, once before initiation of antiviral treatment and again at least 6 months later; were done for all the patients enrolled in the study. The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) that was comparable to that of the control group (33.4 ± 5 ng/ml). The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where an effective therapy improves vitamin D levels. Meanwhile it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.